Last reviewed · How we verify
Ecnoglutide Medium Dosage
Ecnoglutide Medium Dosage is a GLP-1 receptor agonist Small molecule drug developed by Hangzhou Sciwind Biosciences Co., Ltd.. It is currently in Phase 3 development for Type 2 diabetes mellitus. Also known as: XW003.
Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control.
Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control. Used for Type 2 diabetes mellitus.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ecnoglutide Medium Dosage |
|---|---|
| Also known as | XW003 |
| Sponsor | Hangzhou Sciwind Biosciences Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Ecnoglutide binds to and activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. This mechanism also slows gastric emptying and promotes satiety, contributing to improved blood glucose control and potential weight reduction in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Gastrointestinal disturbances
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ecnoglutide Medium Dosage CI brief — competitive landscape report
- Ecnoglutide Medium Dosage updates RSS · CI watch RSS
- Hangzhou Sciwind Biosciences Co., Ltd. portfolio CI
Frequently asked questions about Ecnoglutide Medium Dosage
What is Ecnoglutide Medium Dosage?
How does Ecnoglutide Medium Dosage work?
What is Ecnoglutide Medium Dosage used for?
Who makes Ecnoglutide Medium Dosage?
Is Ecnoglutide Medium Dosage also known as anything else?
What drug class is Ecnoglutide Medium Dosage in?
What development phase is Ecnoglutide Medium Dosage in?
What are the side effects of Ecnoglutide Medium Dosage?
What does Ecnoglutide Medium Dosage target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: Hangzhou Sciwind Biosciences Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: XW003
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing